Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272307 | 0.83 | SMPD3 (0.47) | CYP1A1CYP1A2CYP1B1SRCZAP70 | |
| SCHEMBL313100 | 0.78 | CYP19A1 (0.40) | CYP1A1CYP1A2CYP1B1CYP19A1KDM4E | |
| SCHEMBL12732312 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2TACR3RAB9A | |
| SCHEMBL12055102 | 0.77 | CYP1A2 (0.46) | CYP1A1CYP1A2CYP1B1SRCZAP70 | |
| SCHEMBL1536729 | 0.77 | CYP3A4 (0.51) | KDM4EALDH1A1SMN1; SMN2TACR3TLR8 | |
| SCHEMBL8273118 | 0.77 | CYP1A1 (0.46) | CYP1A1CYP1A2CYP1B1SRCZAP70 | |
| SCHEMBL996348 | 0.77 | SMPD3 (0.47) | CYP1A1CYP1A2CYP1B1SRCZAP70 | |
| SCHEMBL6809626 | 0.77 | ALDH1A1 (0.45) | KDM4EALDH1A1SMN1; SMN2TACR3HPGDS | |
| SCHEMBL8138975 | 0.76 | KDM4E (0.42) | CYP1A1CYP1A2CYP1B1CYP19A1KDM4E | |
| SCHEMBL2214881 | 0.76 | POLB (0.47) | CYP19A1KDM4EALDH1A1SMN1; SMN2TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989471-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-02 | — | — | US | disclosed |
| EP-1912995-B1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| EP-1912995-B1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-09-23 | — | — | US | disclosed |
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1912995-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007014919-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | CYP1A1 618/4885CYP1A2 1007/4885CYP1B1 373/4885 |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2B6, SRD5A1, NR5A2 | CYP1A1 50/4885CYP1A2 79/4885CYP1B1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.